A
ASND
Ascendis Pharma
225.00
-5.21-2.26%After Hours: 225.39 +0.39 +0.17%17:25 02/20 EST
OPEN/PREV CLOSE230.52/230.21
TODAY RANGE221.00-230.52
VOL950.47K
MARKET CAP13.94B
52 WEEK RANGE124.06-242.00
AVG VOL (3M)711.83K
% TURNOVER1.53%
TURNOVER--
P/E (TTM)-50.9511
% RANGE3.98%
EPS(TTM)-4.4160
P/E(FORWARD)37.89
P/B-72.9714
BVPS-3.0834
DIVIDEND--
P/S16.50
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP13.52B
SHARES OUTSTANDING61.98M
NEXT EARNINGS04/29-05/04
FREE FLOAT60.09M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)?
TipRanks·4d ago
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)
Simply Wall St·5d ago
Is Ascendis Pharma (ASND) Still Attractive After Its Strong Multi Year Share Price Run?
Simply Wall St·6d ago
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Cooling
TipRanks·02/13 11:39
Barclays Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Simply Wall St·02/13 00:50
Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives
TipRanks·02/13 00:26
Ascendis Pharma Earnings Call Highlights Growth Momentum
Benzinga·02/12 17:44
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
Dow Jones·02/12 17:10
Ascendis Pharma Price Target Raised to $262.00/Share From $246.00 by Oppenheimer
Dow Jones·02/12 17:10
Ascendis Pharma Is Maintained at Outperform by Oppenheimer
Benzinga·02/12 17:01
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $262
Dow Jones·02/12 14:50
Ascendis Pharma Price Target Raised to $273.00/Share From $240.00 by Wedbush
Dow Jones·02/12 14:50
Ascendis Pharma Is Maintained at Outperform by Wedbush
Benzinga·02/12 14:41
Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $273
TipRanks·02/12 14:00
Ascendis Pharma price target raised to $273 from $240 at Wedbush
Same Industry
Name/Symbol
Change%
Price